Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Non-cash Items (2020 - 2023)

Cytek Biosciences (CTKB) has disclosed Non-cash Items for 4 consecutive years, with $4.4 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Non-cash Items rose 39.31% year-over-year to $4.4 million, compared with a TTM value of $4.4 million through Mar 2023, up 39.31%, and an annual FY2022 reading of $37.2 million, down 74.8% over the prior year.
  • Non-cash Items was $4.4 million for Q1 2023 at Cytek Biosciences, down from $37.2 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $147.6 million in Q4 2021 and bottomed at $1.0 million in Q2 2020.
  • Average Non-cash Items over 4 years is $27.0 million, with a median of $9.7 million recorded in 2021.
  • The sharpest move saw Non-cash Items soared 3184.62% in 2021, then plummeted 90.26% in 2022.
  • Year by year, Non-cash Items stood at $11.4 million in 2020, then surged by 1194.37% to $147.6 million in 2021, then crashed by 74.8% to $37.2 million in 2022, then tumbled by 88.18% to $4.4 million in 2023.
  • Business Quant data shows Non-cash Items for CTKB at $4.4 million in Q1 2023, $37.2 million in Q4 2022, and $4.2 million in Q3 2022.